Health Arcutis Presents New Phase 2 Long-Term Data Showing Globe News Wire Jan 14, 2023 During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1…